Introduction
Trivalent influenza vaccines (IIV3s) containing antigens of two influenza A strains (A/H1N1, A/H3N2) and one influenza B strain are effective in protecting against influenza [1, 2] . As new influenza variants arise via frequent antigenic change, the influenza strains included in IIV3s frequently change between influenza seasons, based on recommendations by the World Health Organization (WHO) [3] .
The 2009 H1N1 pandemic raised the question of whether existing seasonal IIV3s might provide protection against this novel influenza strain. Early analyses of stored sera from vaccine trials demonstrated limited antibody reactivity to this new virus; therefore, IIV3s were predicted to be of no benefit [4, 5] . Over the course of the pandemic, numerous observational studies of IIV3 effectiveness were conducted and yielded conflicting results [6] , suggesting seasonal vaccines to be protective [7] [8] [9] [10] [11] [12] , ineffective [13] [14] [15] [16] [17] , or even detrimental [18] against influenza due to the pandemic H1N1 strain. A meta-analysis of 8 case-control studies with low risk of bias found that IIV3 s provided moderate cross-protection against laboratory-confirmed pandemic H1N1 influenza [19] . However, few randomized controlled trials have addressed this question.
The onset of the 2009 H1N1 pandemic in Australia and New Zealand coincided with the second year of a large, phase 4, randomized, placebo-controlled, efficacy study of a seasonal IIV3 (Fluvax 
Materials and methods

Study design
This phase 4, randomized, observer-blinded, placebocontrolled, efficacy study enrolled healthy adults aged 18 to less than 65 years over two consecutive influenza seasons (2008 and 2009) across 25 sites in Australia and New Zealand. The purpose of this study was to evaluate the clinical efficacy, safety, and tolerability of a IIV3 (Fluvax Ò , CSL Limited, Parkville, Victoria, Australia).
All participants provided written informed consent under ethics approval from each participating institution and the study was conducted in accordance with the Declaration of Helsinki. Healthy, non-pregnant adults were eligible for enrollment if they were 18 years to less than 65 years old at the time of vaccination. Main exclusion criteria were: allergy to any of the vaccine components; medically unstable clinical condition; planned or current pregnancy; lactation; history of Guillain-Barré Syndrome; confirmed or suspected immunosuppressive condition; current or recent immunosuppressive therapy; concurrent participation in a clinical trial or use of an investigational compound; or recommended for seasonal influenza vaccination according to guidelines in Australia [20] or New Zealand [21] . Participants enrolled in 2008 were ineligible to be enrolled in 2009.
Randomization and masking
Participants were randomized in a 2:1 ratio to receive a single injection of 0.5 mL IIV3 or placebo, administered intramuscularly into the deltoid muscle (23 gauge needle, 0.6 mm wide, 25 mm long). As there was a visual difference between IIV3 and placebo, study personnel who were involved in the preparation and administration of the study vaccine had no further involvement in the study conduct. Participants and investigational site staff involved in performing study assessments remained blinded to treatment allocation.
The randomization code was prepared by a statistician, employed by CSL Limited, with the use of SAS software (version 9.1.3; SAS Institute, Cary, NC, USA), using simple block randomization to maintain approximate allocation balance.
Vaccines and placebo
The two commercially available study vaccines fulfilled all of the applicable regulatory requirements and were composed of World Health Organization recommended strains for the South- 15 lg of each hemagglutinin antigen from the respective influenza strains per 0.5 mL dose. The thimerosal-free vaccine was prepared in the allantoic fluid of embryonated chicken eggs as previously described [22] . Placebo consisted of vaccine diluent and was composed of saline, dibasic sodium phosphate, and monobasic sodium phosphate. Batch numbers for the 2008 vaccine and placebo were 00749112A and FLUPLACEBO, respectively; batch numbers for the 2009 vaccine and placebo were 04749111A and IV313248B1, respectively.
Safety assessments
Solicited adverse events (AEs) and oral temperature were recorded in diary cards on the evening of vaccination and every evening for the next 4 days. Unsolicited AEs that occurred on the day of vaccination and for the 20 days after were recorded in diary cards. Information regarding the occurrence of serious adverse events (SAEs) was collected from the day of vaccination to 180 days after study vaccination. A data monitoring committee was established according to United States Food and Drug Administration guidelines [23] .
Clinical and laboratory outcomes
Stimulated by weekly reminder contacts from investigators, participants reported signs and symptoms of an influenza-like illness (ILI) from day 14 after vaccination until 30 November of the respective study year, the time typically marking the end of influenza circulation in the Southern Hemisphere. An ILI was defined as at least one respiratory symptom (e.g., cough, sore throat, nasal congestion) and at least one systemic symptom (e.g., fever P37.8°C [oral], feverishness, chills, body aches). This broad case definition was chosen to maximize the chance of detecting influenza infections. Participants who reported signs and symptoms of an ILI had nose and throat swab specimens collected within 72 h of symptom onset for laboratory confirmation of influenza infection. Laboratory-confirmed influenza was defined as a nose or throat specimen testing positive by viral culture and/or realtime reverse transcription polymerase chain reaction (rRT-PCR, Focus Diagnostics, Cypress, CA, USA). Laboratory-confirmed cases were typed to determine whether they matched the strains included in the vaccine. Except for those specimens identified to be 2009 H1N1 by rRT-PCR, influenza strain typing was determined by gene sequencing (for A subtypes H1N1 and H3N2) or pyrosequencing (for B strains) performed by the WHO Collaborating Centre (Melbourne, Australia) [24] .
Statistical analysis
Vaccine efficacy was assessed for each influenza virus type and subtype only for laboratory-confirmed cases that occurred 14 or more days after vaccination and before 30 November of each trial year. Vaccine efficacy was defined as the relative reduction in influenza rate in the IIV3 group relative to the placebo group, i.e., vaccine efficacy = 1 -(IIV3 recipient infection rate/placebo recipient infection rate). The primary analysis tested whether vaccine efficacy versus placebo was significantly greater than or equal to 40%. The primary endpoint was achieved if the lower bound of the (1 À 2a) Â 100% confidence interval (CI) for vaccine efficacy was 40% or higher.
The study was designed as a 2-year study with an interim analysis after the first season. A Pocock alpha-spending function was used to maintain an overall one-sided a = 0.025 for the primary endpoint, whereby in the first season a = 0.01550 and in the second season a = 0.01387. Assuming an influenza attack rate of at least 3% and a vaccine efficacy of at least 70%, then a first season sample size of N = 7500 randomized participants in a 2:1 ratio to active vaccine and placebo (N = 5000 and 2500, respectively), with a 10% drop-out rate, yields at least 90% power for a one-sided test of vaccine efficacy being greater than 40% using a = 0.01550 (PASS 2005, NCSS, LLC, Kaysville, UT, USA).
The primary analysis assessed vaccine efficacy against any influenza infection and infections caused by vaccine-matched strains. A post hoc analysis of efficacy against non-vaccine strains was also carried out to assess cross-protection. In addition, for the 2009 season, where most cases were of the pandemic H1N1 strain, vaccine efficacy was also analyzed by age strata (17-39 years, 40-54 years, and 55-65 years).
Results
Demographic and baseline clinical characteristics
The first year of the study was conducted between 25 Fig. 1 ). The mean age of participants was 35.5 years and 9.6% reported having received a seasonal influenza vaccine during the 12 months before entering the study (Table 1 ). Approximately 90% of participants were White and approximately 55% were female. Most (63%) had never previously received an influenza vaccination, and most were nonsmokers.
Protocol violations occurred in 41 (0.3%) participants and were distributed equally between study arms (IIV3 group: 28 [0.3%] participants; placebo group: 13 [0.3%] participants). Note that 2 participants aged 17 years and 2 participants aged 65 years were enrolled in the study and included in the evaluable population. (Table 1 ). All 140 participants were excluded from the efficacy analysis before unblinding. An additional 40 participants who took other prohibited medications (e.g., immunosuppressive therapy) were excluded from the efficacy analysis before unblinding.
Concomitant medications
Vaccine efficacy
In the 2008 and 2009 influenza seasons combined, laboratoryconfirmed influenza was identified in 222 of 9889 (2.2%) IIV3 recipients and 192 of 4960 (3.9%) placebo recipients ( Table 2 ). The incidence of laboratory-confirmed influenza due to vaccinematched strains was low during both study years (Table 2) . Of the 179 participants with laboratory-confirmed influenza identified in the IIV3 and placebo groups in 2008, 107 (59.8%) were caused by influenza B strain; 64 of the 107 (59.8%) influenza B strains were antigenically dissimilar to the vaccine strains ( 21 .6%; however, the CIs were wide and included 0 (95% CI: À56.3%, 60.7%). However, the differences in vaccine efficacy between age groups were not statistically significant for the 2009 pandemic H1N1 strain (logistic regression analysis, p = 0.416).
In contrast, post hoc analysis by age suggested similar vaccine efficacy against matched strains across 2008 and 2009 between age groups. In participants 55-65 years of age, vaccine efficacy against all matched strains was 68.4% (95% CI: 3.7%, 89.6%), whereas in participants 17-39 years of age, vaccine efficacy was 55.1% (95% CI: 30.3%, 71.1%). Vaccine efficacy in participants 40-54 years of age was 66.7% (95% CI: 37.2%, 82.3%). The differences in vaccine efficacy between age groups were not statistically significant for the matched strains (logistic regression analysis, p = 0.683).
Adverse events
No vaccine-related deaths or SAEs were reported. One or more solicited local AEs were reported by 74.6% of IIV3 recipients and by 20.4% of placebo recipients (p < 0.001; Fig. 2A ). Pain and injection-site tenderness were the most frequently reported local AEs. Solicited systemic AEs were less common than local events, with one or more AEs reported by 46.6% of IIV3 recipients and 39.1% of placebo recipients (p < 0.001; Fig. 2B ). Malaise, headache, and myalgia were the most frequently reported systemic AEs in both groups. The majority of solicited local and systemic AEs were of mild to moderate intensity and of limited duration (less than 3 days). The frequency of unsolicited AEs was similar between treatment groups (IIV3 group: 33.9%; placebo group: 35.1%).
Discussion
Despite being conducted during two influenza seasons with substantial mismatch between vaccine and circulating influenza strains (in 2008, influenza B was the predominant circulating type whereas in 2009, pandemic A(H1N1)pdm09 was predominant [25] ), this large, randomized, placebo-controlled trial Cross-reactive antibodies may be vaccine strain-specific or boosting of antibodies directed at earlier influenza strains to which the individual was exposed. We observed a boosting of cross-reactive antibodies in our clinical trials of monovalent 2009 H1N1 vaccine in adults and children in Australia [26, 27] , where individuals who had previously received 2009 IIV3 had higher pre-vaccination antibody titers to 2009 H1N1 than those who had not received the vaccine. The findings of the current study are supported by data from other studies of antibody crossreactivity in individuals before and after receipt of IIV3 [28] , although in those studies the effect was greater for those aged over 60 years [4, 29] ; the magnitude of efficacy was highest in those over 55 years in our study. This further suggests that protective efficacy may be a result of cross-protective immunity from multiple vaccinations or exposure to a related virus earlier in life, i.e., some degree of original antigenic sin. Induction of cross-reactive T cell responses to conserved viral epitopes may also be a factor underlying the cross-protection observed in this study [30] . Table 2 Laboratory-confirmed influenza cases, attack rates, and vaccine efficacy (overall, against vaccine-matched strains, and against non-vaccine strains). This randomized controlled study demonstrated protection by seasonal IIV3 against laboratory-confirmed 2009 H1N1 influenza in adults. Two other randomized controlled studies that have investigated the efficacy of seasonal IIV3s against the 2009 pandemic H1N1 strain were conducted in children in Hong Kong [31, 32] . The first small pilot study (N = 119) conducted during 2009 found no evidence of protection (or harm), but was not powered to investigate this outcome [30] . The second larger study (N = 796) conducted in 2009-2010 showed children who received IIV3 had a reduced risk of pandemic influenza A, with a vaccine efficacy estimate of 47% (95% CI, 15-67%) [32] .
The 2008 and 2009 IIV3s were generally well tolerated, with no safety concerns identified. It should be noted that the subsequent 2010 IIV3 was associated with an unexpected increase in postmarketing reports of febrile seizure compared with previous seasonal IIV3 s, predominantly in children <5 years of age. This was likely due to the combination of the new influenza strains included in the 2010 IIV3 and the CSL standard method of manufacture. This method preserved strain-specific viral components of the new influenza strains, heightening immune activation of innate immune cells, which, in a small proportion of children <5 years of age, was associated with the occurrence of febrile seizures [33, 34] . No patient in the current study reported febrile seizures during the study period.
The strengths of this study were the randomized, placebocontrolled design, relatively large size, and use of a clinical efficacy endpoint rather than a serological surrogate endpoint. As such, the study was less subject to the potential sources of bias and confounding associated with the previously reported observational studies. Nevertheless, this study is subject to certain limitations. There was no description of the clinical course of influenza infection among vaccinated and unvaccinated cases, so we cannot report the impact of vaccination on the course of illness or associated co-morbidity. Our study population was limited to healthy adults 17-65 years of age (mean, 35 years), so we cannot address the impact of seasonal IIV3 on preventing 2009 H1N1 in children, a group more immunologically naive to influenza. Most subjects were also female, non-smokers, influenza-vaccine naïve, white, and not Hispanic. In addition, our study did not measure serologic endpoints for influenza infection and, therefore, we can report efficacy only against symptomatic influenza infection.
The formulations for the 2009 Southern Hemisphere and 2009/10 Northern Hemisphere contained identical influenza A strains. As the monovalent H1N1 vaccine was not available during the first wave of the 2009 influenza pandemic, this study suggests that any use of seasonal vaccine in either the Southern or Northern Hemisphere may have had a positive impact on mitigating the peak incidence of pandemic H1N1 infections. Pre-pandemic mathematical modelling indicated that a vaccine, even one with low efficacy, used early in a pandemic could have meaningful benefit in reducing the amplitude of the pandemic wave [35] . 
Conclusions
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